According to estimates of a recent market study by Persistence Market Research (PMR), the global diabetic nephropathy market is poised to exhibit a CAGR of 5.6% from 2014 to 2020. The report, titled “Global Market Study on Diabetic Nephropathy: Asia to Witness Highest Growth by 2020”, states that the market, with a valuation of US$2,262.2 million in 2014, is expected to reach US$3,145.9 million in 2020.
Request Customize Full TOC: http://www.persistencemarketresearch.com/toc/3375
The report is a comprehensive analysis of data pertaining to market dynamics, which include market drivers, trends, restraints, and recent developments in the diabetic nephropathy market.
According to the report, high incidence of diabetes and obesity worldwide is one of the primary factors responsible for growth of the diabetic nephropathy market. In addition, huge R&D investments for drug development by large pharmaceutical companies such as Sanofi, Mitsubishi Tanabe Pharma, and Eli Lilly are contributing to the growth of this market.
Request Sample Report: http://www.persistencemarketresearch.com/samples/3375
Moreover, increasing general health awareness and information about diabetes and kidney conditions is aiding this market.
However, strict regulatory compliances and tedious product approval processes, combined with inadequate therapeutic management for diabetic nephropathy, challenge this market.
For fast results and higher efficacy, combination therapy is a trend that has come to the fore for diabetic nephropathy and is gaining traction in the diabetic nephropathy market, adds the report.
Diabetic nephropathy is a kidney disease that develops as one of the most serious complications for patients with diabetes. Due to the complexity of the condition, which is a combination of several factors, the disease is associated with significant morbidity and mortality for diabetic patients.
Diabetic nephropathy is a condition distinguished by macroalbuminuria. On any given day, the presence of more than 300 milligrams of albumin in the urine is known as macroalbuminuria. In addition, proteinuria, hypertension, and imbalanced filtration rate of the glomerulus are also associated with diabetic nephropathy.
In the event of imbalanced filtration rate of the kidney glomerulus, waste builds in the blood, increasing the protein level in the urine. Major symptoms of late stage diabetic nephropathy are increased albumin levels in urine, ankle and leg swelling, itching, nausea, anemia, high blood pressure, high level of serum creatinine and blood urea nitrogen (BUN), morning weakness, and vomiting.
Among the modes of treatment, disease modifying therapies (DMT) are the largest and fastest growing mode for diabetic nephropathy. DMT is further sub-divided into angiotensin-converting enzyme (ACE), diuretics, calcium channel blockers (CCBs), angiotensin II receptors blockers (ARBs), and others.
Angiotensin-converting enzyme (ACE) accounts as the largest and fastest growing DMT inhibitor for diabetic nephropathy.
ACE inhibitors such as enalapril, ramipril, captopril, and lisinopril lower the protein content in urine, which works towards treating diabetic nephropathy. Angiotensin II receptors blockers (ARBs) and ACE inhibitors combined can offer greater protection to the kidneys than what they individually do.
North America dominates the diabetic nephropathy market, trailed by Europe. China and Japan are emerging as the fastest growing markets for diabetic nephropathy, due to the increasing prevalence of diabetes and growing rate of kidney diseases in these countries.
Browse Full PDF: Diabetic Nephropathy Market